Study Complete
Sponsor ID
20130102
Single-Ascending Dose study of AMG 333 in healthy subjects and subjects with migraines
Study Details
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines. As part of the secondary objectives, this study will characterize the pharmacokinetic (PK) profile of AMG 333, as well as characterize the effect of AMG 333 on the cold pressor test (CPT)-induced increase in blood pressure after single oral doses in healthy subjects and subjects with migraines
Protocol Summary
Primary Outcome Measures
Primary
Timeframe: Up to 29 days
Primary
Timeframe: Up to 29 days
Secondary Outcome Measures
Secondary Outcome Measures
Timeframe: Up to 29 Days
Secondary
Timeframe: Up to 29 days
Secondary Outcome Measures
Timeframe: Up to 29 Days
Secondary Outcome Measures
Timeframe: Up to 29 Days
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Salt Lake City, UT, United States, 84106
Status
Recruiting